Key result
Maternal anti-Ro and anti-La autoantibodies induce congenital heart block by inhibiting L-type calcium channels.
This review highlights the pathophysiology of congenital heart block induced by maternal anti-Ro and anti-La antibodies via inhibition of L-type calcium channels.
May guide counseling in anti-Ro/La pregnancies; leaves open targeted prevention trials.
Maternal antinuclear antibodies with anti-Ro or anti-La specificity might be pathogenic to the fetus and could induce molecular neonatal pathologies, such as neonatal lupus (NL) with or without congenital heart block (CHB). The cutaneous manifestations of neonatal lupus appear at birth or a few weeks later, and skin lesions may persist for weeks. While CHB is characterized by intrauterine bradycardia or low heart rates at birth and may persist for months, depending on the degree of blockage. Clinical and experimental data demonstrated that anti-Ro and anti-La autoantibodies functionally inhibit L-type calcium channels and induce abnormalities in electrical conduction of the cardiac myocytes. It has been 38 years since the first clinical description of CHB. Presently, the pathophysiology of CHB has been clarified through clinical and basic research studies.
No takes yet. Share an insight, caveat, or question.
Herrera‐Esparza et al. (2015) conducted a review in Neonatal lupus and congenital heart block. Maternal anti-Ro and anti-La antibodies was evaluated. Maternal anti-Ro and anti-La autoantibodies functionally inhibit L-type calcium channels and induce abnormalities in electrical conduction of cardiac myocytes, leading to congenital heart block.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: